Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756674561> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2756674561 endingPage "E242" @default.
- W2756674561 startingPage "E241" @default.
- W2756674561 abstract "Proton therapy (PT) is spreading worldwide as a new treatment modality. Although PT provides a more focused dose distribution on the tumor compared with X-ray therapy, there remains much controversy about its routine use in prostate cancer treatment. This is the first multi-institutional retrospective survey of the long-term outcomes of PT for prostate cancer in Japan. This retrospective analysis comprises prostate cancer patients treated with PT at 7 centers between January 2008 and December 2011 and was approved by each Institutional Review Board. The NCCN classification was used. The biochemical relapse free survival (bRFS) was based on the Phoenix definition (nadir + 2.0 ng/mL). The rates of bRFS, overall survival (OS) and incidence of late gastrointestinal (GI) and genitourinary (GU) toxicities were estimated using the Kaplan-Meier methods. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events version 4.0. The inclusion criteria for this analysis were as follows: (1) histologically confirmed prostate cancer, (2) no lymph node and distant metastasis, (3) Japanese men, (4) no prior radiotherapy, (5) no castration-resistant prostate cancer, (6) minimum follow-up of 6 months for surviving patients, and (7) written informed consent. The very-high risk group based on NCCN criteria was included in the high-risk group. The total number of prostate cancer patients in all institutions during this period was 1,302 and 11 patients were excluded because of above criteria. Therefore, 1,291 patients were analyzed. The number of patients in the low-risk, intermediate-risk, and high-risk groups were 215, 520, and 556, respectively. The median follow-up period of surviving patients was 69 months (range: 7-107). In total, 98.8% of patients were treated using conventional fractionation (1.8-2.0GyE) schedule (70-82 GyE/35-41 Fr) and 1.2% of patients were treated by hypofractionation schedule (63-66 GyE/ 21-22 Fr); 58.5% and 21.5 %of patients received neoadjuvant and adjuvant androgen deprivation therapy, respectively. The 5-year rates of bRFS and OS in the low-risk, intermediate-risk, and high-risk patients were 97.0%, 91.1%, 83.1% for bRFS, and 98.4%, 96.8%, 95.2% for OS, respectively. T classification, Gleason score, and NCCN classification were significant prognostic factors for bRFS in multivariate analysis. The incidence of grade 2 late GI and GU toxicities were 3.6% and 2.6%, retrospectively, but grade 3 toxicities were observed only 6 and 4 patients, respectively. This retrospective analysis of a multi-institutional survey suggested that PT is favorable and well tolerated for prostate cancer. Based on this result, multi-institutional prospective clinical trial for patients with intermediate risk group will be started to define its role in the treatment of prostate cancer in Japan." @default.
- W2756674561 created "2017-10-06" @default.
- W2756674561 creator A5004916187 @default.
- W2756674561 creator A5005492528 @default.
- W2756674561 creator A5014097069 @default.
- W2756674561 creator A5018944066 @default.
- W2756674561 creator A5034835804 @default.
- W2756674561 creator A5049584975 @default.
- W2756674561 creator A5057618408 @default.
- W2756674561 creator A5070732334 @default.
- W2756674561 creator A5074150160 @default.
- W2756674561 creator A5078379631 @default.
- W2756674561 creator A5079971690 @default.
- W2756674561 creator A5087824756 @default.
- W2756674561 creator A5091639568 @default.
- W2756674561 date "2017-10-01" @default.
- W2756674561 modified "2023-10-18" @default.
- W2756674561 title "Long-Term Outcomes of Proton Therapy for Prostate Cancer in Japan: Retrospective Analysis of a Multi-institutional Survey" @default.
- W2756674561 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1181" @default.
- W2756674561 hasPublicationYear "2017" @default.
- W2756674561 type Work @default.
- W2756674561 sameAs 2756674561 @default.
- W2756674561 citedByCount "0" @default.
- W2756674561 crossrefType "journal-article" @default.
- W2756674561 hasAuthorship W2756674561A5004916187 @default.
- W2756674561 hasAuthorship W2756674561A5005492528 @default.
- W2756674561 hasAuthorship W2756674561A5014097069 @default.
- W2756674561 hasAuthorship W2756674561A5018944066 @default.
- W2756674561 hasAuthorship W2756674561A5034835804 @default.
- W2756674561 hasAuthorship W2756674561A5049584975 @default.
- W2756674561 hasAuthorship W2756674561A5057618408 @default.
- W2756674561 hasAuthorship W2756674561A5070732334 @default.
- W2756674561 hasAuthorship W2756674561A5074150160 @default.
- W2756674561 hasAuthorship W2756674561A5078379631 @default.
- W2756674561 hasAuthorship W2756674561A5079971690 @default.
- W2756674561 hasAuthorship W2756674561A5087824756 @default.
- W2756674561 hasAuthorship W2756674561A5091639568 @default.
- W2756674561 hasConcept C121608353 @default.
- W2756674561 hasConcept C126322002 @default.
- W2756674561 hasConcept C141071460 @default.
- W2756674561 hasConcept C143998085 @default.
- W2756674561 hasConcept C167135981 @default.
- W2756674561 hasConcept C207103383 @default.
- W2756674561 hasConcept C2776235491 @default.
- W2756674561 hasConcept C2777106319 @default.
- W2756674561 hasConcept C2777416452 @default.
- W2756674561 hasConcept C2777793932 @default.
- W2756674561 hasConcept C2777899217 @default.
- W2756674561 hasConcept C2780192828 @default.
- W2756674561 hasConcept C44249647 @default.
- W2756674561 hasConcept C509974204 @default.
- W2756674561 hasConcept C71924100 @default.
- W2756674561 hasConceptScore W2756674561C121608353 @default.
- W2756674561 hasConceptScore W2756674561C126322002 @default.
- W2756674561 hasConceptScore W2756674561C141071460 @default.
- W2756674561 hasConceptScore W2756674561C143998085 @default.
- W2756674561 hasConceptScore W2756674561C167135981 @default.
- W2756674561 hasConceptScore W2756674561C207103383 @default.
- W2756674561 hasConceptScore W2756674561C2776235491 @default.
- W2756674561 hasConceptScore W2756674561C2777106319 @default.
- W2756674561 hasConceptScore W2756674561C2777416452 @default.
- W2756674561 hasConceptScore W2756674561C2777793932 @default.
- W2756674561 hasConceptScore W2756674561C2777899217 @default.
- W2756674561 hasConceptScore W2756674561C2780192828 @default.
- W2756674561 hasConceptScore W2756674561C44249647 @default.
- W2756674561 hasConceptScore W2756674561C509974204 @default.
- W2756674561 hasConceptScore W2756674561C71924100 @default.
- W2756674561 hasIssue "2" @default.
- W2756674561 hasLocation W27566745611 @default.
- W2756674561 hasOpenAccess W2756674561 @default.
- W2756674561 hasPrimaryLocation W27566745611 @default.
- W2756674561 hasRelatedWork W1012954095 @default.
- W2756674561 hasRelatedWork W1135596034 @default.
- W2756674561 hasRelatedWork W1969194629 @default.
- W2756674561 hasRelatedWork W2085529113 @default.
- W2756674561 hasRelatedWork W2138863125 @default.
- W2756674561 hasRelatedWork W2400503820 @default.
- W2756674561 hasRelatedWork W2529939135 @default.
- W2756674561 hasRelatedWork W2597301728 @default.
- W2756674561 hasRelatedWork W2761204422 @default.
- W2756674561 hasRelatedWork W4243514755 @default.
- W2756674561 hasVolume "99" @default.
- W2756674561 isParatext "false" @default.
- W2756674561 isRetracted "false" @default.
- W2756674561 magId "2756674561" @default.
- W2756674561 workType "article" @default.